At the same time, in SCLC, where the oncogenic impact of Notch signaling is less clear, a combined RBP-jκ/MAML3 inhibition reduced SCLC sensitivity to gemcitabine, which is possibly explainable by the inhibition of proliferation under RBP-jκ/MAML3 suppression [587]. Here, RBPJ is linked to small cell lung carcinoma.